Intelligence / Healthtech & medtech market map / Clinical and regulatory support services / Quality, compliance and lifecycle regulatory services / Pharma & biotech GMP quality systems, inspection readiness and audit remediation
Pharma & biotech GMP quality systems, inspection readiness and audit remediation
Design, implementation and remediation of GMP/GxP quality systems for pharmaceutical and biotechnology manufacturers — site quality manuals, SOPs, qualification and validation support, data-integrity remediation, inspection-readiness mock audits and responses to FDA Form 483 observations, warning letters and EU non-compliance reports. Buyer is the pharma or biotech manufacturer; the job is to hold a GMP-compliant, inspection-ready operating system; the trigger is an inspection, a data-integrity finding, a new site or a new product launch.
- Level
- Niche
- Segmented by
- Customer type
- Buyers
- Pharmaceutical and biotechnology manufacturers, including CDMO-owned sites and virtual/contract organisations
- Buying centre
- Head of Quality Assurance / Qualified Person (owner), Site Head or VP Operations (budget), Head of Manufacturing and Head of Regulatory Affairs (stakeholders)
- FDA or EMA GMP inspection and Form 483 / observation responses
- Data-integrity (ALCOA+) findings and warning-letter remediation
- New manufacturing site, tech transfer or capacity expansion
- Launch of a new molecule, fill-finish site or cold-chain capability
- Inspection findings and warning letters that put product on hold
- Data-integrity gaps in batch records and laboratory systems
- Quality documentation written for one regulator that fails another
- Internal audit and CAPA backlogs that slow tech transfer and launch
How this was sized
$2.2B ($1.8B–$2.7B) · 2025 · Proxy
Anchor: pharma regulatory-affairs outsourcing of USD 7.5B (2024) to USD 8.9B (2025), forecast USD 15.7–16.2B by 2034 at 7–7.6% p.a. [1]. Source [1] also lists a separate 'Quality and GMP' workload line but the figure is truncated in the supplied extract, so no published number is available for it. Quality-system implementation, audit and inspection-readiness work assumed to be 20–30% of the USD 8.9B pharma regulatory outsourcing pool (USD 1,780–2,670M; midpoint USD 2,200M). Forecast applies the published 7.6% CAGR: 2,200 x 1.076^9 = USD 4,215M, rounded to USD 4,200M in 2034. Share assumption unverified; Low confidence.
- Pharma Outsourcing and Software Market Size: CRO, PV, QMS
askdona.com · 2026-10-31
Alongside it in Quality, compliance and lifecycle regulatory services
// Sell into Pharma & biotech GMP quality systems, inspection readiness and audit remediation